Search

Your search keyword '"van Gelder, Michel"' showing total 16 results
Start Over Author "van Gelder, Michel" Journal bone marrow transplantation
16 results on '"van Gelder, Michel"'

1. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Guièze, Romain, primary, Eikema, Diderik-Jan, additional, Koster, Linda, additional, Schetelig, Johannes, additional, Sengeloev, Henrik, additional, Passweg, Jakob, additional, Finke, Jürgen, additional, Arat, Mutlu, additional, Broers, Annoek E. C., additional, Stölzel, Friedrich, additional, Byrne, Jenny, additional, Castilla-Llorente, Cristina, additional, Dreger, Peter, additional, Eder, Matthias, additional, Gedde-Dahl, Tobias, additional, Kröger, Nicolaus, additional, Ribera Santasusana, Josep Maria, additional, Richardson, Deborah, additional, Rambaldi, Alessandro, additional, Yañez, Lucrecia, additional, Van Gelder, Michel, additional, Drozd-Sokolowska, Joanna, additional, Raj, Kavita, additional, Yakoub-Agha, Ibrahim, additional, Tournilhac, Olivier, additional, and McLornan, Donal P., additional

Published
2024
Full Text
View/download PDF

2. The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT

Author

Tournilhac, Olivier, primary, van Gelder, Michel, additional, Eikema, Dirk-Jan, additional, Zinger, Nienke, additional, Dreger, Peter, additional, Bornhäuser, Martin, additional, Vucinic, Vladan, additional, Scheid, Christof, additional, Cornelissen, Jan J., additional, Schroeder, Thomas, additional, Jindra, Pavel, additional, Sengeloev, Henrik, additional, Nguyen Quoc, Stephanie, additional, Stelljes, Matthias, additional, Blau, Igor Wolfgang, additional, Mayer, Jiri, additional, Paneesha, Shankara, additional, Chevallier, Patrice, additional, Forcade, Edouard, additional, Kröger, Nicolaus, additional, Blaise, Didier, additional, Gribben, John, additional, Nielsen, Bendt, additional, Johansson, Jan-Erik, additional, Kyriakou, Charalampia, additional, Beguin, Yves, additional, Pioltelli, Pietro, additional, Sampol, Antònia, additional, McLornan, Donal P., additional, Schetelig, Johannes, additional, Hayden, Patrick J., additional, and Yakoub-Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

3. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

4. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Author

Schetelig, Johannes, primary, Hoek, Jennifer, additional, Stilgenbauer, Stephan, additional, Middeke, Jan Moritz, additional, Andersen, Niels Smedegaard, additional, Fox, Christopher P., additional, Lenhoff, Stig, additional, Volin, Liisa, additional, Shimoni, Avichai, additional, Schroyens, Wilfried, additional, van Gelder, Michel, additional, Bunjes, Donald, additional, van Biezen, Anja, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Kröger, Nicolaus, additional, Yakoub-Agha, Ibrahim, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

5. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2020
Full Text
View/download PDF

6. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, primary, Hoek, Jennifer, additional, Stilgenbauer, Stephan, additional, Middeke, Jan Moritz, additional, Andersen, Niels Smedegaard, additional, Fox, Christopher P., additional, Lenhoff, Stig, additional, Volin, Liisa, additional, Shimoni, Avichai, additional, Schroyens, Wilfried, additional, van Gelder, Michel, additional, Bunjes, Donald, additional, van Biezen, Anja, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Kröger, Nicolaus, additional, Yakoub-Agha, Ibrahim, additional, and Dreger, Peter, additional

Published
2020
Full Text
View/download PDF

7. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Author

Dreger, Peter, primary, Michallet, Mauricette, additional, Bosman, Paul, additional, Dietrich, Sascha, additional, Sobh, Mohamad, additional, Boumendil, Ariane, additional, Nagler, Arnon, additional, Scheid, Christof, additional, Cornelissen, Jan, additional, Niederwieser, Dietger, additional, Müller, Lutz, additional, Vandenberghe, Elizabeth, additional, Scortechini, Ilaria, additional, Schoemans, Helene, additional, Andersen, Niels S., additional, Finke, Jürgen, additional, Russo, Domenico, additional, Ljungman, Per, additional, Passweg, Jakob, additional, van Gelder, Michel, additional, Durakovic, Nadira, additional, Labussiere-Wallet, Helene, additional, Berg, Tobias, additional, Wulf, Gerald, additional, Bethge, Wolfgang, additional, Bunjes, Donald, additional, Stilgenbauer, Stefan, additional, Canepari, Maria Elisa, additional, Schaap, Michel, additional, Fox, Christopher P., additional, Kröger, Nicolaus, additional, Montoto, Silvia, additional, and Schetelig, Johannes, additional

Published
2018
Full Text
View/download PDF

8. Allogeneic hematopoietic cell transplantation for patients with TP53mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2021
Full Text
View/download PDF

9. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Abstract

No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/delCLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II–IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.

Published
2021
Full Text
View/download PDF

10. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Author

Michallet, Mauricette, Dreger, Peter, Sobh, Mohamad, Koster, Linda, Hoek, Jennifer, Boumendil, Ariane, Scheid, Christof, Fox, Christopher P., Wulf, Gerald, Krüger, William, van Gelder, Michel, Corradini, Paolo, Russo, Domenico, Passweg, Jakob, Schoemans, Hélène, Bethge, Wolfgang, Schaap, Nicolaas, Cornelissen, Jan, Browne, Paul, Durakovic, Nadira, Muller, Lutz, Montoto, Silvia, Kroger, Nicolaus, and Schetelig, Johannes

Abstract

The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35–64) and the median number of treatment lines prior to transplantation was 3 (1–10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1–140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52–84) and 50% (95% CI: 32–66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.

Published
2020
Full Text
View/download PDF

11. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

12. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2022
Full Text
View/download PDF

14. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study.

Author

Schetelig J, Hoek J, Stilgenbauer S, Middeke JM, Andersen NS, Fox CP, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede LC, Tournilhac O, Kröger N, Yakoub-Agha I, and Dreger P

Subjects
Humans, Prospective Studies, Transplantation, Homologous, Tumor Suppressor Protein p53 genetics, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell therapy
Published
2021
Full Text
View/download PDF

15. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Author

Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, and Schetelig J

Subjects
Adenine analogs & derivatives, Adult, Aged, Allografts, Disease-Free Survival, Female, Humans, Male, Middle Aged, Piperidines, Survival Rate, Graft vs Host Disease mortality, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphoma, Mantle-Cell mortality, Lymphoma, Mantle-Cell therapy, Pyrazoles administration & dosage, Pyrimidines administration & dosage
Abstract

The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

Published
2019
Full Text
View/download PDF

16. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.

Author

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, and Kröger N

Subjects
Adult, Aged, Cyclophosphamide therapeutic use, Female, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation mortality, Humans, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Retrospective Studies, Survival Analysis, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Transplantation, Haploidentical mortality
Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results